Hospital
Preston Memorial Hospital Corporation
Preston Memorial Hospital Corporation was paid $20.15M by Medicaid between Jan 2018 and Dec 2024, across 175 billing codes. Its largest line is 99285, emergency room visit (most serious) — 11% of everything it billed.
33Billing provider infoPRESTON MEMORIAL HOSPITAL CORPORATION
KINGWOOD, WV 26537
KINGWOOD, WV 26537
33aNPI1013950054assigned 06/14/2006
33bProvider typeCritical Access Hospital
28Total paid$20.15M
24GClaims276,030
24DCodes billed175
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in West Virginia
Rank by total paid#2 of 24
Median peer was paid$3.57M
This provider vs. median5.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 50,055 | $4.71M | |
| 2019 | 33,302 | $2.46M | |
| 2020 | 53,920 | $4.50M | |
| 2021 | 51,123 | $3.57M | |
| 2022 | 30,266 | $1.77M | |
| 2023 | 33,405 | $1.95M | |
| 2024incomplete | 23,959 | $1.19M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 6,697 | 5,398 | $2.22M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.0% | 7,150 | 6,060 | $1.60M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.7% | 9,156 | 7,946 | $1.55M |
| 80053 | Comprehensive metabolic panel | 6.8% | 14,903 | 12,516 | $1.37M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.7% | 772 | 694 | $1.15M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.3% | 37,385 | 29,751 | $659K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.0% | 14,088 | 11,329 | $607K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.0% | 6,900 | 1,796 | $595K |
| 80306 | 2.7% | 2,962 | 1,987 | $554K | |
| 70450 | Computed tomography, head or brain; without contrast material | 2.7% | 1,467 | 1,343 | $550K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.6% | 527 | 492 | $522K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.8% | 6,188 | 5,271 | $353K |
163 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | 1.7% | 3,852 | $346K |
| G0378 | Hospital observation service, per hour | 1.5% | 703 | $301K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.4% | 4,281 | $286K |
| 36415 | Collection of venous blood by venipuncture | 1.3% | 14,568 | $269K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.3% | 3,564 | $263K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 2,551 | $262K |
| 84484 | 1.2% | 5,552 | $237K | |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.2% | 1,877 | $234K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.1% | 4,558 | $218K |
| 81001 | <1% | 4,403 | $198K | |
| 83735 | <1% | 5,562 | $181K | |
| 83690 | <1% | 3,691 | $180K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,562 | $179K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 8,676 | $177K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,023 | $170K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,451 | $158K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,319 | $157K |
| 83605 | <1% | 3,306 | $155K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,186 | $152K |
| 82150 | <1% | 2,239 | $141K | |
| 97014 | <1% | 2,472 | $140K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 819 | $140K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,782 | $128K |
| 82550 | <1% | 2,542 | $124K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,098 | $123K |
| 82553 | <1% | 2,185 | $119K | |
| 87040 | <1% | 1,169 | $110K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 263 | $107K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 167 | $99K |
| J3490 | Unclassified drugs | <1% | 1,193 | $98K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,426 | $96K |
| 84703 | <1% | 1,136 | $92K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,721 | $88K |
| 83880 | <1% | 1,239 | $83K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,040 | $81K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,073 | $80K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,945 | $80K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,103 | $77K |
| 85027 | <1% | 1,675 | $75K | |
| 96376 | <1% | 677 | $72K | |
| 80061 | Lipid panel | <1% | 2,742 | $71K |
| 80305 | <1% | 439 | $67K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,100 | $66K |
| 85610 | <1% | 2,676 | $64K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,168 | $62K |
| 85379 | <1% | 1,137 | $60K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 192 | $59K |
| 85007 | <1% | 1,232 | $58K | |
| 74022 | <1% | 437 | $54K | |
| 85730 | <1% | 1,641 | $52K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 366 | $51K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 730 | $50K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,349 | $50K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 539 | $50K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 427 | $46K |
| 73610 | <1% | 500 | $42K | |
| 73562 | <1% | 469 | $41K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,298 | $40K |
| 86140 | <1% | 763 | $40K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 28 | $39K |
| 84145 | <1% | 939 | $38K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,551 | $37K |
| 71250 | <1% | 79 | $37K | |
| 73130 | <1% | 389 | $37K | |
| 73630 | <1% | 433 | $37K | |
| 87186 | <1% | 1,003 | $37K | |
| 80050 | General health panel | <1% | 346 | $35K |
| 87077 | <1% | 1,013 | $33K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 133 | $33K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 58 | $32K |
| 0099U | <1% | 58 | $31K | |
| J2704 | Injection, propofol, 10 mg | <1% | 619 | $30K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 3,156 | $28K |
| 81025 | <1% | 689 | $26K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 291 | $23K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 620 | $22K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 460 | $22K |
| 81003 | <1% | 1,312 | $20K | |
| 72110 | <1% | 143 | $20K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,215 | $19K |
| 73110 | <1% | 199 | $19K | |
| 84439 | <1% | 607 | $18K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 355 | $17K |
| 82803 | <1% | 173 | $17K | |
| 82948 | <1% | 670 | $17K | |
| 73030 | <1% | 203 | $17K | |
| 96367 | <1% | 66 | $17K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 43 | $17K |
| 73590 | <1% | 167 | $16K | |
| 81002 | <1% | 1,187 | $16K | |
| 82607 | <1% | 277 | $16K | |
| 97161 | <1% | 150 | $16K | |
| 74018 | <1% | 219 | $16K | |
| 92551 | <1% | 983 | $14K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 605 | $14K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 536 | $13K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 134 | $12K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 17 | $11K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 474 | $11K |
| 87581 | <1% | 118 | $9K | |
| 87486 | <1% | 118 | $9K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 106 | $9K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 66 | $8K |
| 94664 | <1% | 174 | $8K | |
| 73564 | <1% | 75 | $8K | |
| 86308 | <1% | 154 | $7K | |
| 97162 | <1% | 53 | $7K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 61 | $6K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 124 | $6K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,083 | $6K |
| 85651 | <1% | 215 | $5K | |
| 84100 | <1% | 276 | $5K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 127 | $5K |
| 87070 | <1% | 74 | $5K | |
| 80074 | <1% | 66 | $4K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 93 | $4K |
| 90686 | <1% | 520 | $4K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 121 | $4K |
| 73560 | <1% | 55 | $4K | |
| 87807 | <1% | 27 | $4K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 342 | $3K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 32 | $3K |
| 86580 | <1% | 242 | $3K | |
| 82043 | <1% | 120 | $3K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 12 | $3K |
| 83540 | <1% | 158 | $3K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 484 | $3K |
| 84702 | <1% | 32 | $3K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 94 | $2K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 204 | $2K |
| 83550 | <1% | 102 | $2K | |
| 0002A | <1% | 71 | $2K | |
| 82565 | <1% | 110 | $2K | |
| 82570 | <1% | 92 | $1K | |
| 82728 | <1% | 79 | $1K | |
| 87081 | <1% | 32 | $986.92 | |
| 0001A | <1% | 55 | $953.04 | |
| 82746 | <1% | 15 | $928.46 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 62 | $917.19 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 158 | $896.09 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 15 | $868.08 |
| 80320 | <1% | 72 | $852.16 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 30 | $850.80 |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 38 | $732.60 |
| 99490 | Ccm add 20min | <1% | 208 | $694.66 |
| 91320 | <1% | 16 | $678.60 | |
| 94760 | <1% | 126 | $646.25 | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 48 | $542.92 |
| 84520 | <1% | 28 | $458.32 | |
| 20610 | <1% | 20 | $350.81 | |
| 85018 | <1% | 20 | $339.01 | |
| 86592 | <1% | 42 | $288.70 | |
| 90662 | <1% | 131 | $233.91 | |
| 11721 | <1% | 17 | $173.40 | |
| 86376 | <1% | 15 | $168.02 | |
| 90656 | <1% | 14 | $158.79 | |
| G0008 | Administration of influenza virus vaccine | <1% | 222 | $114.79 |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 16 | $23.45 |
| 90653 | <1% | 15 | $12.63 | |
| 90480 | <1% | 16 | $0.97 | |
| 91300 | <1% | 26 | $0.11 | |
| 90734 | <1% | 15 | $0.03 | |
| 80349 | 0% | 29 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLOCKWOOD, MELISSA (PRESIDENT AND CEO)
| Provider | Location | Paid |
|---|---|---|
| Preston Memorial Hospital Corporation | Kingwood, WV | $2.63M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.